阻塞性睡眠呼吸暂停及其持续气道正压通气治疗对急性冠脉综合征患者心血管事件发生率的影响(ISAACC研究):一项随机对照试验
ISAACC研究为西班牙15家医院开展的多中心、开放标签、平行组随机对照试验,纳入因急性冠脉综合征入院的无嗜睡患者,入院后24-72小时行呼吸多导描记。存在阻塞性睡眠呼吸暂停者按1:1随机分至持续气道正压通气联合常规治疗组或单纯常规治疗组,另设无阻塞性睡眠呼吸暂停的参照组。中位随访3.35年,持续气道正压通气组与常规治疗组心血管复合事件发生率相似(16% vs 17%;HR 0.89,95%CI 0.68-1.17;p=0.40),参照组与常规治疗组亦相似(15% vs 17%;HR 1.01,95%CI 0.76-1.35;p=0.93)。
要点
- 无嗜睡的急性冠脉综合征患者中,阻塞性睡眠呼吸暂停未增加心血管复合事件发生率(参照组15% vs 常规治疗组17%;HR 1.01,95%CI 0.76-1.35;p=0.93)。
- 持续气道正压通气治疗未显著降低心血管复合事件发生率(16% vs 17%;HR 0.89,95%CI 0.68-1.17;p=0.40)。
- 持续气道正压通气平均依从时间为2.78小时/晚(SD 2.73),心血管事件发生率似乎与持续气道正压通气依从性或阻塞性睡眠呼吸暂停严重程度无关。
- 持续气道正压通气组629例中464例(74%)发生1538次严重不良事件,常规治疗组626例中406例(65%)发生1764次严重不良事件。
适用人群与场景
- 西班牙15家医院因急性冠脉综合征入院、有明确症状记录的无嗜睡成年患者(男女,年龄≥18岁),入院后24-72小时行呼吸多导描记。
- 另纳入急性冠脉综合征但无阻塞性睡眠呼吸暂停的患者作为参照组。
诊断标准与关键阈值
- 阻塞性睡眠呼吸暂停依据入院后24-72小时呼吸多导描记诊断。
- 主要终点为随访至少1年时心血管复合事件的发生率,包括心血管死亡或非致死性事件(急性心肌梗死、非致死性卒中、因心力衰竭住院、因不稳定型心绞痛或短暂性脑缺血发作新发住院)。
处置流程与药物剂量
- 阻塞性睡眠呼吸暂停患者随机分至持续气道正压通气联合常规治疗组或单纯常规治疗组。
- 持续气道正压通气组平均依从时间为2.78小时/晚(SD 2.73)。
- 随访时间点:纳入时、1个月、3个月、6个月、12个月、18个月、24个月、30个月、36个月,此后如适用每12个月随访一次。
研究设计与关键结果
- 多中心、开放标签、平行组随机对照试验,西班牙15家医院,2011年4月25日至2018年2月2日共2834例急性冠脉综合征患者行呼吸多导描记,2551例(90.01%)被纳入。
- 1264例(49.55%)存在阻塞性睡眠呼吸暂停,随机分至持续气道正压通气组(n=633)或常规治疗组(n=631);1287例(50.45%)无阻塞性睡眠呼吸暂停,其中603例(46.85%)随机分至参照组。
- 中位随访3.35年(IQR 1.50-5.31)。
- 主要终点:持续气道正压通气组98次事件(16%)vs 常规治疗组108次事件(17%);HR 0.89(95%CI 0.68-1.17);p=0.40。
- 参照组90次事件(15%)vs 常规治疗组102次事件(17%);HR 1.01(95%CI 0.76-1.35);p=0.93。
- 心血管事件发生率似乎与持续气道正压通气依从性或阻塞性睡眠呼吸暂停严重程度无关。
- 严重不良事件:持续气道正压通气组629例中464例(74%)发生1538次;常规治疗组626例中406例(65%)发生1764次。
证据类型、等级与局限
- 证据类型:多中心、开放标签、平行组随机对照试验,主要分析按意向性治疗原则进行。
- 因干预性质,试验干预无法对研究者或患者设盲。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在无嗜睡的急性冠脉综合征患者中,阻塞性睡眠呼吸暂停的存在与心血管事件发生率升高无关,持续气道正压通气治疗未显著降低该发生率(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite the improvement in the prognosis of acute coronary syndrome (ACS), substantial morbidity and mortality remain. We aimed to evaluate the effect of obstructive sleep apnoea (OSA) and its treatment with continuous positive airway pressure (CPAP) on the clinical evolution of patients with ACS.
METHODS: We designed a multicentre, open-label, parallel-group, randomised controlled trial of patients with ACS at 15 hospitals in Spain. Eligible non-sleepy patients were men and women aged 18 years and older, admitted to hospital for documented symptoms of ACS. All patients underwent respiratory polygraphy during the first 24-72 h after admission. OSA patients were randomly assigned (1:1) to CPAP treatment plus usual care (CPAP group) or usual care alone (UC group) by a computerised system available 24 h a day. A group of patients with ACS but without OSA was also included as a reference group. Because of the nature of the intervention, the trial intervention could not be masked to either investigators or patients. Patients were monitored and followed for a minimum of 1 year. Patients were examined at the time of inclusion; after 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months; and every 12 months thereafter, if applicable, during the follow-up period. The primary endpoint was the prevalence of a composite of cardiovascular events (cardiovascular death or non-fatal events [Acute myocardial infarction, non-fatal stroke, hospital admission for heart failure, and new hospitalisations for unstable angina or transient ischaemic attack]) in patients followed up for a minimum of 1 year. The primary analysis was done according to the intention-to-treat principle. This study is registered with Clinicaltrials.gov, NCT01335087 and is now closed.
FINDINGS: Between April 25, 2011, and Feb 2, 2018, a total of 2834 patients with ACS had respiratory polygraphy, of whom 2551 (90·01%) were recruited. 1264 (49·55%) patients had OSA and were randomly assigned to the CPAP group (n=633) or the UC group (n=631). 1287 (50·45%) patients did not have OSA, of whom 603 (46·85%) were randomly assigned to the reference group. Patients were followed up for a median of 3·35 years (IQR 1·50-5·31). The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up. Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73). The prevalence of cardiovascular events was similar between patients in the reference group (90 [15%] events) and those in the UC group (102 (17%) events) during follow-up (1·01 [0·76-1·35]; p=0·93). The prevalence of cardiovascular events seem not to be related to CPAP compliance or OSA severity. 464 (74%) of 629 patients in the CPAP group had 1538 serious adverse events and 406 (65%) of 626 patients in the UC group had 1764 serious adverse events.
INTERPRETATION: Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.
FUNDING: ResMed (Australia), Fondo de Investigación Sanitaria (Fondo Europeo de Desarrollo Regional), the Spanish Respiratory Society, the Catalonian Cardiology Society, Esteve-Teijin, Oxigen Salud, and ALLER.
参考来源
- Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Respir Med. 2019. PMID: 31839558. doi:10.1016/S2213-2600(19)30271-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。